MedDataX Logo

Safety and Tolerability of an Intravenous Infusion of ACZ885 in Patients With Wet Age-Related Macular Degeneration

NCT ID: NCT00503022

Last Updated: 2007-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the tolerability and safety of a single intravenous infusion of ACZ885. It also explores the efficacy of the compound in central macular edema and visual acuity in patients with wet age-related macular edema.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wet Age-Related Macular Degeneration

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Wet age-related macular degeneration ACZ885

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACZ885

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female ≥ 50 years old, with aged related macular degeneration
* Patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration

Exclusion Criteria

* Active intraocular inflammation or ocular infection in the study eye
* Eye disease that may result in visual loss during the study
* Chronic therapy with topical, local or systemic corticosteroids.
* Pregnant or nursing (lactating) women.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis EH 001 862 778 8300

Role: STUDY_CHAIR

COREC,UK

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bern, , Switzerland

Site Status

Belfast, Northern Ireland, , United Kingdom

Site Status

Bristol, , United Kingdom

Site Status

Liverpool, , United Kingdom

Site Status

London, , United Kingdom

Site Status

Nottingham, , United Kingdom

Site Status

Southampton, , United Kingdom

Site Status

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CACZ885F2201

Identifier Type: -

Identifier Source: org_study_id